Abstract | BACKGROUND: METHODS: By March 2013, data were available from 41 of the 45 patients completing the trial with a median follow-up after therapy discontinuation of 42 months (range 1-60). Three patients withdrew during the original study and one failed to respond to either of the therapies. No patient received a diagnosis alternative to CIDP during the follow-up. RESULTS: Twenty-eight of the 32 patients treated with IVIg (as primary or secondary therapy after failing to respond to IVMP) improved after therapy (87.5%) as compared with 13 of the 24 patients treated with IVMP as primary or secondary therapy (54.2%). After a median follow-up of 42 months (range 1-57), 24 out of 28 patients responsive to IVIg (85.7%) worsened after therapy discontinuation. The same occurred in 10 out of 13 patients (76.9%) responsive to IVMP (p=0.659) after a median follow-up of 43 months (range 7-60). Worsening occurred 1-24 months (median 4.5) after IVIg discontinuation and 1-31 months (median 14) after IVMP discontinuation (p=0.0126). CONCLUSIONS: A similarly high proportion of patients treated with IVIg or IVMP eventually relapse after therapy discontinuation but the median time to relapse was significantly longer after IVMP than IVIg. This difference may help to balance the more frequent response to IVIg than to IVMP in patients with CIDP.
|
Authors | Eduardo Nobile-Orazio, Dario Cocito, Stefano Jann, Antonino Uncini, Paolo Messina, Giovanni Antonini, Raffaella Fazio, Francesca Gallia, Angelo Schenone, Ada Francia, Davide Pareyson, Lucio Santoro, Stefano Tamburin, Guido Cavaletti, Fabio Giannini, Mario Sabatelli, Ettore Beghi, IMC Trial Group |
Journal | Journal of neurology, neurosurgery, and psychiatry
(J Neurol Neurosurg Psychiatry)
Vol. 86
Issue 7
Pg. 729-34
(Jul 2015)
ISSN: 1468-330X [Electronic] England |
PMID | 25246645
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. |
Chemical References |
- Anti-Inflammatory Agents
- Immunoglobulins, Intravenous
- Immunologic Factors
- Methylprednisolone
|
Topics |
- Anti-Inflammatory Agents
(administration & dosage, therapeutic use)
- Humans
- Immunoglobulins, Intravenous
(administration & dosage, therapeutic use)
- Immunologic Factors
(administration & dosage, therapeutic use)
- Methylprednisolone
(administration & dosage, therapeutic use)
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
(drug therapy, epidemiology, prevention & control)
- Recurrence
- Retrospective Studies
- Time Factors
- Treatment Outcome
|